APA (7th ed.) Citation

A, V., V, C., J, S., G, L., A, T., G, R., . . . L, C. (2026). Association between canakinumab dose and long-term remission in Still's disease: Insights from the AIDA network registry. Frontiers in pharmacology, 17, 1846937. https://doi.org/10.3389/fphar.2026.1846937

Chicago Style (17th ed.) Citation

A, Vitale, et al. "Association Between Canakinumab Dose and Long-term Remission in Still's Disease: Insights from the AIDA Network Registry." Frontiers in Pharmacology 17 (2026): 1846937. https://doi.org/10.3389/fphar.2026.1846937.

MLA (9th ed.) Citation

A, Vitale, et al. "Association Between Canakinumab Dose and Long-term Remission in Still's Disease: Insights from the AIDA Network Registry." Frontiers in Pharmacology, vol. 17, 2026, p. 1846937, https://doi.org/10.3389/fphar.2026.1846937.